MedMira Board of Directors Elected at Annual Shareholders Meeting
HALIFAX, Jan. 29, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, today announced that
the Company's Board of Directors was elected at MedMira's 2013 Annual General
and Special Meeting of Shareholders, which was held on January 25(th), 2013.
Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile
were re-elected as Directors of the Company. Dr. Michael Sidler, a
representative of the Company's majority shareholder, OnSite Lab Holding AG,
was also elected.
"We are very pleased to welcome Dr. Sidler to our Board of Directors," said
Hermes Chan, CEO and Director, MedMira. "His expertise in investment and
technology commercialization in early-stage companies will make a significant
contribution to our Board's role in strategic oversight and business execution
as we position ourselves for growth in 2013."
Shareholders approved all other matters considered at the meeting including
the appointment of Deloitte as the Company's auditors and ratification of the
stock option plan.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. MedMira is the only Canadian company to be
awarded US Army contracts for the development of rapid tests for HIV and
Hepatitis viruses. The Company's testing solutions provide hospitals, labs,
clinics and individuals with reliable, rapid diagnosis for diseases such as
HIV and hepatitis C in just three minutes. The Company's tests are sold under
the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira is
located in Halifax, Nova Scotia, Canada. www.medmira.com.
This news release contains forward-looking statements, including statements
relating to growth in the Company's business, earnings and profitability, and
trends in demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation regarding future
events including statements regarding possible future growth and new business
opportunities. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Andrea Young, Corporate Communications Tel: 902-450-1588
SOURCE: MEDMIRA INC.
To view this news release in HTML formatting, please use the following URL:
CO: MEDMIRA INC.
ST: Nova Scotia
NI: BTC 2575 WNEWS
-0- Jan/29/2013 16:48 GMT
Press spacebar to pause and continue. Press esc to stop.